AGIO
Agios Pharmaceuticals, Inc.
$40.06
+0.45
(+1.14%)
Mkt Cap
2.38B
Volume
622,645
52W Range
22.24-46
Sector
Healthcare
Beta
0.54
EPS (TTM)
-7.25
P/E Ratio
-3.82
Revenue (TTM)
66.05M
Rev Growth (5Y)
-2.8%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$132.80
Undervalued
strong signal
69.8% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Stable Earnings Power
30.0 / 100 pillar composite (overridden)
Steady, predictable earnings power — graded A–F vs. similar companies.
Company Description
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 54.03M | 36.50M | 26.82M | 14.24M | 0 | 0 | 117.91M | 94.39M | 43.01M | 69.89M | 59.12M | 65.36M |
| Net Income | (412.78M) | 673.73M | (352.09M) | (231.80M) | 1.60B | (327.37M) | (411.47M) | (346.03M) | (314.67M) | (198.47M) | (117.73M) | (53.50M) |
| EPS | -7.12 | 11.86 | -6.33 | -4.23 | -6.36 | -4.74 | -6.61 | -6.03 | -6.75 | -5.07 | -3.15 | -1.59 |
| Free Cash Flow | (377.29M) | (391.53M) | (297.06M) | (314.36M) | (413.06M) | (304.87M) | (382.79M) | (311.41M) | (289.86M) | 28.65M | (97.11M) | (61.57M) |
| FCF / Share | -6.51 | -6.89 | -5.34 | -5.74 | -6.83 | -4.42 | -6.38 | -5.42 | -6.22 | 0.73 | -2.59 | -1.83 |
| Operating CF | (372.98M) | (389.84M) | (296.06M) | (309.48M) | (407.32M) | (290.76M) | (370.62M) | (304.42M) | (285.23M) | 38.56M | (76.95M) | (59.35M) |
| Total Assets | 1.30B | 1.66B | 937.12M | 1.24B | 1.44B | 852.95M | 890.74M | 858.46M | 614.40M | 619.09M | 420.06M | 491.90M |
| Total Debt | 62.02M | 56.99M | 72.00M | 85.66M | 97.09M | 105.20M | 113.66M | 0 | 0 | 0 | 0 | 0 |
| Cash & Equiv | 89.13M | 76.25M | 88.20M | 139.26M | 203.13M | 127.44M | 80.93M | 805.42M | 567.75M | 573.56M | 375.91M | 14.03M |
| Book Value | 1.19B | 1.54B | 811.02M | 1.10B | 1.29B | 399.50M | 640.53M | 687.54M | 375.50M | 358.59M | 345.12M | 424.37M |
| Return on Equity | -0.35 | 0.44 | -0.43 | -0.21 | 1.24 | -0.82 | -0.64 | -0.50 | -0.84 | -0.55 | -0.34 | -0.13 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 20.75M | 19.97M | 12.88M | 12.46M | 8.73M | 10.73M | 8.96M | 8.62M | 8.19M | 7.10M | 7.40M | 6.71M |
| Net Income | (99.11M) | (108.04M) | (103.43M) | (112.02M) | (89.29M) | (96.52M) | 947.91M | (96.12M) | (81.55M) | (95.94M) | (91.32M) | (83.81M) |
| EPS | -1.69 | -1.85 | -1.78 | -1.93 | -1.55 | -1.69 | 16.65 | -1.69 | -1.45 | -1.72 | -1.64 | -1.51 |
| Free Cash Flow | (119.69M) | (97.33M) | (89.71M) | (78.00M) | (112.25M) | (134.13M) | (84.64M) | (72.75M) | (100.01M) | (72.72M) | (62.01M) | (66.75M) |
| FCF / Share | -2.04 | -1.67 | -1.54 | -1.35 | -1.95 | -2.35 | -1.49 | -1.28 | -1.77 | -1.30 | -1.11 | -1.20 |
| Operating CF | (118.92M) | (96.21M) | (88.15M) | (77.12M) | (111.49M) | (133.17M) | (84.22M) | (72.59M) | (99.87M) | (72.49M) | (61.64M) | (66.75M) |
| Total Assets | 1.18B | 1.30B | 1.39B | 1.47B | 1.56B | 1.66B | 1.79B | 773.06M | 849.71M | 937.12M | 1.01B | 1.09B |
| Total Debt | 35.74M | 40.21M | 44.52M | 48.76M | 52.94M | 56.99M | 60.83M | 64.62M | 68.35M | 72.00M | 75.50M | 78.95M |
| Cash & Equiv | 113.60M | 89.13M | 92.71M | 80.87M | 78.96M | 76.25M | 253.73M | 84.52M | 118.76M | 88.20M | 64.33M | 84.75M |
| Book Value | 1.11B | 1.19B | 1.28B | 1.37B | 1.47B | 1.54B | 1.63B | 660.51M | 743.92M | 811.02M | 886.84M | 964.24M |
| Return on Equity | -0.09 | -0.09 | -0.08 | -0.08 | -0.06 | -0.06 | 0.58 | -0.15 | -0.11 | -0.12 | -0.10 | -0.09 |
AGIO News
Here's Why Shares in Novo Nordisk Rival, Agios Pharmaceutical, Soared This Week
AGIO's Filing for Mitapivat in SCD Gets FDA's Priority Tag, Stock Up
Strength Seen in Agios Pharmaceuticals (AGIO): Can Its 17.7% Jump Turn into More Strength?
Here's Why Agios Pharmaceuticals Stock Soared Today (Hint: It's FDA-Related)
Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone
U.S. FDA Grants Priority Review to Agios' sNDA for Mitapivat in Sickle Cell Disease
Agios to Host Second Quarter 2026 Financial Results Conference Call and Webcast on July 30 at 8:00 a.m. ET
AGIO Stock Surges 35% in Six Months: What's Driving It?
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor Event Transcript